Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Taiwan Liposome Company"},{"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 \u2013 Inhalable Liposome Formulations of Antiviral Drugs for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Taiwan Liposome Company"},{"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Medigen Vaccine Biologics"},{"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"United BioPharma"},{"company":"United BioPharma","sponsor":"Shanghai Public Health Clinical Centre","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"United BioPharma"},{"company":"TaiGen Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Filed U.S IND for Its Influenza Antiviral TG-1000","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"TaiGen Biotechnology"},{"company":"TaiGen Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"TaiGen Biotechnology"}]

United BioPharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621

Details:

UB-621 is a first-in-class anti-gD mAb a best-in-class long-acting treatment for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2).

Lead Product(s): UB-621

Therapeutic Area: Infections and Infectious Diseases Product Name: UB-621

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Shanghai Public Health Clinical Centre

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 18, 2021

ASK
US

Upload
your Pipeline Activity

Taiwan Liposome Company

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19

Details:

GS-441524 (named ISPM21) is main plasma metabolite of the antiviral prodrug remdesivir. Studies on inhalable liposomal ISPM21 showed significantly higher concentrations in the lungs than their conventional counterparts.

Lead Product(s): ISPM21

Therapeutic Area: Infections and Infectious Diseases Product Name: GS-441524

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 23, 2021

ASK
US

Upload
your Pipeline Activity

United BioPharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes

Details:

The current Phase 2 study is a randomized, single-blinded, placebo-controlled study to investigate the efficacy and safety of single dose UB-621 treatment for recurrent genital herpes.

Lead Product(s): UB-621

Therapeutic Area: Infections and Infectious Diseases Product Name: UB-621

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 11, 2020

ASK
US

Upload
your Pipeline Activity

TaiGen Biotechnology

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000

Details:

TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.

Lead Product(s): TG-1000

Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 02, 2020

ASK
US

Upload
your Pipeline Activity

Taiwan Liposome Company

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)

Details:

In preclinical studies, TLC19 demonstrated 30-fold exposure in the lungs while achieving lower blood and heart exposure than oral HCQ and unformulated HCQ.

Lead Product(s): Hydroxychloroquine Sulphate

Therapeutic Area: Infections and Infectious Diseases Product Name: TLC19

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 14, 2020

ASK
US

Upload
your Pipeline Activity

Medigen Vaccine Biologics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy

Details:

The first participant in MVC's Phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant at National Taiwan University Hospital in early October.

Lead Product(s): S-2P vaccine,CpG 1018

Therapeutic Area: Infections and Infectious Diseases Product Name: S-2P vaccine

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Dynavax Technologies

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 13, 2020

ASK
US

Upload
your Pipeline Activity

TaiGen Biotechnology

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

TaiGen Filed U.S IND for Its Influenza Antiviral TG-1000

Details:

TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.

Lead Product(s): TG-1000

Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 05, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY